文献速递癫痫

IDH野生型胶质母细胞瘤患者肿瘤演变过程中肿瘤相关癫痫的特征与预后

Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With IDH Wild-Type Glioblastoma.
PubMed 文献 · Neurology · 2023-12-13

肿瘤相关癫痫累积发生率随肿瘤演变从诊断时33.1%升至临终期51.8%,未控制的癫痫发作从20.1%升至41.1%。诊断时肿瘤相关癫痫是更长总生存期的独立预测因素(校正HR 0.78,95%CI 0.67-0.90,p<0.001)。

要点

  • 肿瘤相关癫痫累积发生率随胶质母细胞瘤演变从诊断时33.1%升至临终期51.8%。
  • 未控制的癫痫发作随肿瘤演变从诊断时20.1%升至临终期41.1%。
  • 诊断时肿瘤相关癫痫与更长总生存期独立相关(校正HR 0.78,95%CI 0.67-0.90,p<0.001)。

核心结论

  • 肿瘤相关癫痫随IDH野生型胶质母细胞瘤演变而进展,手术对癫痫控制有影响,支持合理使用抗癫痫药物和最大安全切除;肿瘤相关癫痫是更长生存期的独立预测因素。

研究设计与样本

  • 观察性、回顾性单中心研究,在一家三级转诊神经肿瘤外科中心(2000-2020年)开展。
  • 采用χ2或Fisher精确检验分析分类变量,非配对t检验或Mann-Whitney秩和检验分析连续变量。
  • 将单因素分析中与肿瘤相关癫痫或癫痫控制相关的预测因素纳入向后逐步logistic回归模型。

主要发现

  • 肿瘤相关癫痫累积发生率随肿瘤演变增加:诊断时33.1%,肿瘤治疗后44.7%,进展时52.4%,临终期51.8%。
  • 肿瘤相关癫痫与肿瘤特征相关(皮层受累、无坏死、体积小)。
  • 未控制的癫痫发作随肿瘤演变增加:诊断时20.1%,肿瘤治疗后32.0%,进展时46.7%,临终期41.1%。
  • 肿瘤治疗后癫痫控制与癫痫特征(肿瘤治疗前未控制、局灶至双侧强直-阵挛发作)及切除范围相关。
  • 肿瘤进展时癫痫控制与癫痫特征(诊断时存在、肿瘤治疗后未控制)及进展时间相关。

临床怎么用

  • 原文未据此给出推荐;作者在讨论中认为,肿瘤相关癫痫随IDH野生型胶质母细胞瘤演变而进展以及手术对癫痫控制的影响,支持合理使用抗癫痫药物和最大安全切除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Tumor-related epilepsy is a well-known symptom of glioblastoma. However, the particular characteristics of epileptic seizures related to glioblastoma, isocitrate dehydrogenase (IDH)-wild-type is almost unexplored longitudinally during the whole course of the disease. We assessed tumor-related epilepsy and seizure control during tumor evolution and the prognostic significance of tumor-related epilepsy. METHODS: We performed an observational, retrospective single-center study at one tertiary referral neuro-oncology surgical center (2000-2020). We included adult patients treated for a newly diagnosed supratentorial glioblastoma, IDH-wild-type with available preoperative and postoperative MRI and with available epileptic seizure status at diagnosis. To determine factors associated with tumor-related epilepsy or seizure control, univariate analyses were performed using the χ2 or Fisher exact tests for categorical variables and the unpaired t test or Mann-Whitney rank-sum test for continuous variables. Predictors associated with tumor-related epilepsy and seizure control in unadjusted analysis were entered into backward stepwise logistic regression models. RESULTS: One thousand six patients were enrolled. The cumulative incidence of tumor-related epilepsy increased during tumor evolution (33.1% at diagnosis, 44.7% after oncologic treatment, 52.4% at progression, and 51.8% at the end-of-life phase) and is related to tumor features (cortex involvement, no necrosis, and small volume). Uncontrolled epileptic seizures increased during tumor evolution (20.1% at diagnosis, 32.0% after oncologic treatment, 46.7% at progression, and 41.1% at the end-of-life phase). Epileptic seizure control after oncologic treatment was related to seizure features (uncontrolled before oncologic treatment and focal-to-bilateral tonic-clonic seizures) and to the extent of resection. Epileptic seizure control at tumor progression was related to seizure features (presence at diagnosis and uncontrolled after oncologic treatment) and to the time to progression. Tumor-related epilepsy at diagnosis was a predictor of a longer overall survival (adjusted hazard ratio, 0.78; 95% CI 0.67-0.90; p < 0.001) independent of age, Karnofsky Performance Status score, tumor location and volume, extent of resection, standard combined chemoradiotherapy, levetiracetam use, and MGMT promoter methylation. DISCUSSION: The progression of tumor-related epilepsy with the evolution of glioblastoma, IDH-wild-type and the effects of surgery on seizure control argue for proper antiseizure medication and maximal safe resection. Tumor-related epilepsy is an independent predictor of a longer survival.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pallud J, Roux A, Moiraghi A, et al. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With IDH Wild-Type Glioblastoma. Neurology. 2023. PMID: 38165369. doi:10.1212/WNL.0000000000207902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。